ArticleThe Journal of experimental medicine2021
Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients.
Article in The Journal of experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Resolving SARS-CoV-2 CD4Cell reports. Medicine · 2022Pooled it
- Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study.Frontiers in immunology · 2025Trial
- Entering the Age of Specificity in T Cell Immunity.Immunological reviews · 2026Review
- Safety and immunogenicity of an adjuvant-free peptide vaccine targeting IL-17A: Phase 1 randomized controlled trial.iScience · 2026Article
- The Role of CD4 T Cell Repertoire and Immune Memory Mechanisms in Vaccination and Infection Immunity.Immunological reviews · 2026Review
- Article
- Conformational bias in SARS-CoV-2 Spike CD4+ T-cell epitope dominance.Frontiers in immunology · 2026Article
- Development of a peptide-based vaccine using a T cell epitope derived from SARS-CoV-2.iScience · 2025Article
- Effect of prevaccination blood and T-cell phenotypes on antibody responses to a COVID-19 mRNA vaccine.International immunology · 2025Article
- Identification of α-galactosylceramide as an endogenous mammalian antigen for iNKT cells.The Journal of experimental medicine · 2025Article
- A conserved human CD4+ T cell subset recognizing the mycobacterial adjuvant trehalose monomycolate.The Journal of clinical investigation · 2024Article
- Article
- Bob1 maintains T follicular helper cells for long-term humoral immunity.Communications biology · 2024Article
- Sulfated bile acid is a host-derived ligand for MAIT cells.Science immunology · 2024Article
- Structural Framework for Analysis of CD4+ T-Cell Epitope Dominance in Viral Fusion Proteins.Biochemistry · 2023Review
- Comparison of transformations for single-cell RNA-seq data.Nature methods · 2023Article
- Delayed generation of functional virus-specific circulating T follicular helper cells correlates with severe COVID-19.Nature communications · 2023Article
- Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection.Vaccines · 2023Review
- Innate and Adaptive Immunity during SARS-CoV-2 Infection: Biomolecular Cellular Markers and Mechanisms.Vaccines · 2023Review
- Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children.Nature immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 6 institutions in 1 country.
Funding
Abstract
Adaptive immunity is a fundamental component in controlling COVID-19. In this process, follicular helper T (Tfh) cells are a subset of CD4+ T cells that mediate the production of protective antibodies; however, the SARS-CoV-2 epitopes activating Tfh cells are not well characterized. Here, we identified and crystallized TCRs of public circulating Tfh (cTfh) clonotypes that are expanded in patients who have recovered from mild symptoms. These public clonotypes recognized the SARS-CoV-2 spike (S) epitopes conserved across emerging variants. The epitope of the most prevalent cTfh clonotype, S864-882, was presented by multiple HLAs and activated T cells in most healthy donors, suggesting that this S region is a universal T cell epitope useful for booster antigen. SARS-CoV-2-specific public cTfh clonotypes also cross-reacted with specific commensal bacteria. In this study, we identified conserved SARS-CoV-2 S epitopes that activate public cTfh clonotypes associated with mild symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.